Research and Markets: DRG Insight: Rheumatoid Arthritis (G7)

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/ndhznv/drg_insight) has announced the addition of Decision Resources, Inc's new report "DRG Insight: Rheumatoid Arthritis (G7)" to their offering.

DRG Insights takes the most relevant information and insights from across our portfolio for BioPharma and Med-Tech products and delivers the insight heavy perspective that you need to generate better ideas and deliver more successful campaigns and initiatives. The rheumatoid arthritis (RA) therapy market has matured to the point that TNF-a inhibitors are firmly established as first-line biological agents.

Biologics from other drug classes - the interleukin-6 inhibitor tocilizumab (Roche/Chugai's Actemra/RoActemra), the selective costimulation modulator abatacept (Bristol-Myers Squibb/Ono Pharmaceutical's Orencia), and the B-cell-targeted therapy rituximab (Biogen Idec/Roche/Chugai/Zenyaku Kogyo's Rituxan, Roche's MabThera) - underscore the dominance of the TNF-a inhibitors because these newer agents are reserved for patients who fail to achieve an adequate response to TNF-a inhibitor therapy.

For emerging agents, the remaining opportunity is limited and the barrier to entry is high in the absence of clear advantages and improvements over marketed therapies. The pending approval of oral kinase inhibitors with compelling efficacy have the potential, if they are priced less than the biologics, to shift the treatment algorithm to delay initiation of biological therapy.

Key Topics Covered:

Executive Summary

Current Market Landscape

Etiology & Pathophysiology

Staging/Patient Segmentation

Select Drug Targets

Growth Drivers & Constraints

Key Metrics

Population Dynamics

Market Landscape

Current Therapies Treatment Algorithms

Country Specific Decision Trees

Comparison of Key Agents

Expert Insight on Prescribing Trends

Importance of Drug Attributes in Prescribing Decisions

Pricing & Reimbursement

Factors Influencing Pharmacy Director Tier Placement Decisions

Accessibility and Cost Hurdles

Reimbursement Environment

Unmet Needs Emerging Therapies

Near-term Outlook

Long-term Outlook

Important Endpoints in Prescribing Decisions

Timelines

2010 and 2010 sales and Market Share

For more information visit http://www.researchandmarkets.com/research/ndhznv/drg_insight

Source: Decision Resources, Inc